MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: We found that several MEK inhibitors, including refametinib and trametinib, decrease MYC expression in CML cells whereas the PI3‐kinase/mTOR blocker BEZ235 showed no effects.